Avizakimab, formerly known as BOS161721, represents a promising therapeutic approach to treating inflammatory conditions . This monoclonal medication selectively targets interleukin-18 , a crucial protein https://aronihsa934260.pointblog.net/avizakimab-a-thorough-investigation-into-bos161721-s-promise-93226045